Clinical trials and sample size considerations: Another perspective

被引:0
|
作者
Lee, SJ
Zelen, M
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
Type I and II error probabilities; posterior error probabilities; clinical trials; Bayesian inferences;
D O I
暂无
中图分类号
O21 [概率论与数理统计]; C8 [统计学];
学科分类号
020208 ; 070103 ; 0714 ;
摘要
We propose a Bayesian formulation of the sample size problem for planning clinical trials. The frequentist paradigm for calculating sample sizes for clinical trials is to prespecify the type I and II error probabilities. These error probabilities are conditional on the true hypotheses. Instead we propose prespecifying posterior probabilities which are conditional on the outcome of the trial. Our method is easy to implement and has intuitive interpretations. We illustrate an application of our method to the planning of cancer clinical trials for the Eastern Cooperative Oncology Group (ECOG).
引用
收藏
页码:95 / 103
页数:9
相关论文
共 50 条
  • [1] Clinical trials and sample size considerations: Another perspective - Comment
    Simon, R
    Bryant, J
    Day, R
    Lee, SJ
    Zelen, M
    STATISTICAL SCIENCE, 2000, 15 (02) : 103 - 110
  • [2] Considerations on sample size and power calculations in randomized clinical trials
    Karlsson, J
    Engebretsen, L
    Dainty, K
    ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY, 2003, 19 (09): : 997 - 999
  • [3] Power and sample size considerations in clinical trials with competing risk endpoints
    Maki, Ellen
    PHARMACEUTICAL STATISTICS, 2006, 5 (03) : 159 - 171
  • [4] Sample size for clinical trials
    Billings, M.
    Lopez Mitnik, G.
    Dye, B. A.
    ORAL DISEASES, 2017, 23 (08) : 1013 - 1018
  • [5] On the sample size of clinical trials
    Papageorgiou, Spyridon N.
    JOURNAL OF ORTHODONTICS, 2018, 45 (03) : 210 - 212
  • [6] SAMPLE-SIZE CONSIDERATIONS IN VACCINE TRIALS
    BLACKWELDER, WC
    CONTROLLED CLINICAL TRIALS, 1986, 7 (03): : 253 - 253
  • [7] SAMPLE-SIZE CONSIDERATIONS IN VACCINE TRIALS
    ROCKETTE, HE
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1989, 8 (01) : S91 - S93
  • [8] Power, sample size and adaptation considerations in the design of group sequential clinical trials
    Lai, TL
    Shih, MC
    BIOMETRIKA, 2004, 91 (03) : 507 - 528
  • [9] Sample size and design considerations for phase II clinical trials with correlated observations
    Sargent, DJ
    Sloan, JA
    Cha, SS
    CONTROLLED CLINICAL TRIALS, 1999, 20 (03): : 242 - 252
  • [10] Sample Size Verification for Clinical Trials
    Shuster, Jonathan J.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2014, 7 (01): : 60 - 62